Nakagawa, Kenji
Sho, Masayuki http://orcid.org/0000-0002-6208-7661
Fujishiro, Mitsuhiro
Kakushima, Naomi
Horimatsu, Takahiro
Okada, Ken-ichi
Iguchi, Mikitaka
Uraoka, Toshio
Kato, Motohiko
Yamamoto, Yorimasa
Aoyama, Toru
Akahori, Takahiro
Eguchi, Hidetoshi
Kanaji, Shingo
Kanetaka, Kengo
Kuroda, Shinji
Nagakawa, Yuichi
Nunobe, Souya
Higuchi, Ryota
Fujii, Tsutomu
Yamashita, Hiroharu
Yamada, Suguru
Narita, Yukiya
Honma, Yoshitaka
Muro, Kei
Ushiku, Tetsuo
Ejima, Yasuo
Yamaue, Hiroki
Kodera, Yasuhiro
Funding for this research was provided by:
Grant-in-Aid for Scientific Research on Health, Labor and Welfare (H29-GANTAISAKU-IPPAN-013, 20EA1021)
Article History
Received: 15 July 2022
Accepted: 3 September 2022
First Online: 19 October 2022
Declarations
:
: Any financial relationship with enterprises, businesses, or academic institutions in the subject matter or materials discussed in the manuscript are listed as follows: MSD, Ono Pharmaceutical, Medical Beebe Partners, 3D Matrix, Nihon Pharmaceuticals, Fujifilm, Olympus, Tella Pharma, ICON Japan, IQVIA Services Japan, Gunze Medical Japan, Janssen Pharma, Kyorin Pharmaceutical, Covidien Japan, Sanofi, Nippon Kayaku, Johnson & Johnson, Nichi-Iko Pharmaceutical, Central Medical, Terumo, HOYA Pentax, Mitsubishi Tanabe Pharma, Tsumura & Co., EA Pharma, Astellas Pharma, Eisai, Shionogi & Co., Daiichi Sankyo, Taiho Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Bayer Yakuhin, Yakult Honsha, AbbVie, Astra Zeneca, Eli Lilly Japan, Pfizer, Gilead Sciences, Merck Serono, Sumitomo Dainippon Pharma Co., Mediscience Planning Inc., Solasia Pharma, Parexel International Inc., and Amgen Astellas BioPharma.